Pulmonary Hypertension and Imatinib

PROOF OF CONCEPT STUDY ON THE EFFICACY OF INHALATORY TARGETED IMATINIB NANOFORMULATIONS IN PULMONARY HYPERTENSION AND POST-INFLAMMATORY FIBROSIS.

NCT06917196 ·Status: RECRUITING

Trans-pulmonary Biomarkers in Pulmonary Hypertension

NCT01961232 ·Status: ACTIVE_NOT_RECRUITING

Study to Assess Safety and Efficacy of Ambrisentan in Subjects With Pulmonary Arterial Hypertension.

NCT00423748 ·Status: COMPLETED ·Phase: PHASE3

A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial Hypertension

NCT06137742 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2

Efficacy Study of Ambrisentan in Chinese Patients With Pulmonary Arterial Hypertension (PAH)

NCT01808313 ·Status: COMPLETED ·Phase: PHASE3

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess Safety and Efficacy of Ambrisentan in Subjects With Pulmonary Arterial Hypertension.

NCT00423202 ·Status: COMPLETED ·Phase: PHASE3

Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial - Follow Up Long Term Extension (IMPAHCT-FUL)

NCT05557942 ·Status: TERMINATED ·Phase: PHASE3

Long-Term Extension Study of Inhaled Nitric Oxide (iNO) for PAH

NCT02652429 ·Status: UNKNOWN ·Phase: PHASE3

Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension Participants

NCT01392469 ·Status: COMPLETED ·Phase: PHASE3

Exercise Induced Pulmonary Hypertension in Systemic Sclerosis and Treatment With Ambrisentan

NCT01051960 ·Status: COMPLETED ·Phase: PHASE4

Biomarkers in the Diagnosis and Assessment of Pulmonary Arterial Hypertension (PAH)

NCT00566423 ·Status: COMPLETED ·Phase: NA

Bioenergetic Effect of Pioglitazone in CLD-PH

NCT06336798 ·Status: RECRUITING ·Phase: PHASE2

A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)

NCT01178073 ·Status: COMPLETED ·Phase: PHASE3

Discovering Clinical Study Experiences of Patients With Pulmonary Hypertension

NCT05918458 ·Status: NOT_YET_RECRUITING

Upfront Combination Pulmonary Arterial Hypertension Therapy

NCT03809156 ·Status: UNKNOWN ·Phase: PHASE4

Phase 2 Study of Ambrisentan for Liver Function Test Rescue in Pulmonary Arterial Hypertension

NCT00423592 ·Status: COMPLETED ·Phase: PHASE2

Ambrisentan for Early Low-Risk Pulmonary Arterial Hypertension

NCT06987097 ·Status: NOT_YET_RECRUITING ·Phase: NA

Study of PAH Subjects With LTOT Use That Have Demonstrated Improved Exercise Tolerance With the Use of Inhaled Nitric

NCT03602781 ·Status: WITHDRAWN ·Phase: PHASE3

Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH)

NCT01179737 ·Status: TERMINATED ·Phase: PHASE2

An Open-Label Uncontrolled Study of the Safety and Efficacy of Ambrisentan in Participants With Exercise-Induced Pulmonary Arterial Hypertension (PAH)

NCT01338636 ·Status: COMPLETED ·Phase: PHASE4

Biomarkers in Pulmonary Arterial Hypertension Treated With Nilotinib

NCT01320865 ·Status: WITHDRAWN

Study of Ambrisentan in Participants With Pulmonary Hypertension

NCT00777920 ·Status: COMPLETED ·Phase: PHASE3

129 Xenon Imaging in Patients Treated With Sotatercept

NCT06351345 ·Status: RECRUITING ·Phase: PHASE2

Clinical Study of Pulsed, Inhaled Nitric Oxide Versus Placebo in Symptomatic Subjects With PAH

NCT02725372 ·Status: TERMINATED ·Phase: PHASE3

A Study of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1)

NCT02664558 ·Status: COMPLETED ·Phase: PHASE2